

References

- BCSH Blood Transfusion Task Force (1996)** Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. *Transfusion Medicine*, 6, 261–271.
- Bennett, J.M., Catovsky, D., Daniel, M.T., Fladrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1989):** The French–American–British (FAB) proposal for the classification of chronic (mature) B and T lymphoid leukaemias. *Journal of Clinical Pathology*, 42, 567–584.
- Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguët, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Boivin, P., Lesty, C., Duault, M., Monconduit, M., Belabbès, S. & Gremy, F. (1981):** A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. *Cancer*, 48, 198–206.
- Boogaerts, M.A., Van Hoof, A., Catovsky, D., Kovacs, M., Montillo, M., Zinzani, P.L., Binet, J.L., Feremans, W., Marcus, R., Bosch, F., Verhoef, G. & Klein, M. (2001):** Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. *Journal of Clinical Oncology*, 19, 4252–4258.
- Bosanquet, A.G., Johnson, S.A. & Richards, S.M. (1999)** Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. *British Journal of Haematology*, 106, 71–77.

Bosch, F., Ferrer, A., Lopez-Guillermo, A., Gine, E., Bellosillo, B., Villamor, N., Colomor, D., Cobo, F., Esteve, J., Altes, A., Besalduch, J., Ribera, J. & Montserrat, E. (2002) Fludarabine, cyclophosphanide and mitoxauthrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. *British Journal of Haematology*, 119, 976– 984.

Byrd, J.C., Smith, L., Hackbarth, M.L., Flinn, I.W., Young, D., Proffitt, J.H. & Heerema, N.A. (2003a): Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. *Cancer Research*, 63, 36–38.

Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. & Larson, R.A. (2003b): Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). *Blood*, 101, 6–14.

Byrd, J.C., Peterson, B., Piro, L., Saven, A., Vardiman, I.W., Larson, R.A. & Schiffer, C. (2003c) A phase II study of cladribine treatment for fludarabine refractory B-cell chronic lymphocytic leukemia: results from CALGB study 9211. *Leukemia*, 17, 323–327.

Castelli, R., Vismara, A., Pavia, G., Dagani, R. & Porro, T. (2002) Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by

intravenous immunoglobulin concentrate. *Annali Italiani de Medicini Interna*, 17, 47–50.

Catovsky, D., Fooks, J. & Richards, S. (1989) Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. *British Journal of Haematology*, 72, 141–149.

Catovsky, D., Richards, S., Fooks, J. & Hamblin, T. (1991) CLL trials in the United Kingdom. The Medical Research Council CLL Trials 1,2,3. *Leukemia and Lymphoma*, (Suppl.), 105–107.

Chapel, H.M. & Bunch, C. (1987): Mechanisms of infection in chronic lymphocytic leukemia. *Seminars in Hematology*, 24, 291–296.

Chapel, H., Dicato, M., Gamm, H., Brennan, V., Ries, F., Bunch, C. & Lee, M. (1994) Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. *British Journal of Haematology*, 88, 209–212.

Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. *Blood*, 87, 4990–4997.

Chisesi, T., Capnist, G. & Dal Fior, S. (1991) Splenic irradiation in chronic lymphocytic leukemia. *European Journal of Haematology*, 46, 202–204.

Christensen, B.E., Hansen, M.M. & Videbaek, A. (1977) Splenectomy in chronic lymphocytic leukaemia. Scandanavian Journal of Haematology, 18, 279–287.

CLL Trialists' Collaborative Group (1999): Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. CLL Trialists' Collaborative Group. Journal of National Cancer Institute, 91, 861–868.

Cortes, J., O'Brien, S., Loscertales, J., Kantarjian, H., Giles, F., Thomas, D., Koller, C. & Keating, M. (2001) Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer, 92, 2016–2022.

Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez-Guillermo, A., Campo, E. & Montserrat, E. (2003): ZAP-70 expression as a surrogate for immunoglobulinvariable- region mutations in chronic lymphocytic leukemia. New England Journal of Medicine, 348, 1764–1775.

Cusack, Jr, J.C., Seymour, J.F., Lerner, S., Keating, M.J. & Pollock, R.E. (1997) Role of splenectomy in chronic lymphocytic leukemia. Journal of American College of Surgery, 185, 237–243.

Dabaja, B.S., O'Brien, S.M., Kantarjian, H.M., Cortes, J.E., Thomas, D.A., Albitar, M., Schlette, E.S., Faderl, S., Sarris, A., Keating, M.J. & Giles, F.J. (2001) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in

Richter's syndrome. *Leukemia and Lymphoma*, 42, 329–337.

amle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood*, 94, 1840–1847.

Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A.M., Capelli, G., Tamburini, A., Suppo, G., Battaglia, A., Del Principe, M.I., Del Moro, B., Masi, M. & Amadori, S. (2001) Clinical significance of CD38 expression in chronic lymphocytic leukemia. *Blood*, 98, 2633–2639.

Delpero, J.R., Houvenaeghel, G., Gastaut, J.A., Orsoni, P., Blache, J.L., Guerin, G. & Carcassonne, Y. (1990) Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non- Hodgkin's lymphoma. *British Journal of Surgery*, 77, 443–449.

Di Raimondo, F., Giustolisi, R., Lerner, S., Cacciola, E., O'Brien, S., Kantarjian, H. & Keating, M.J. (2001) Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. *Annals of Oncology*, 12, 621–625.

Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus,

B., Binet, J.L. & Travade, P. (1998) Chlorambucil in indolent chronic lymphocytic leukemia. French Co-operative Group on Chronic Lymphocytic Leukemia. New England Journal of Medicine, 338, 1506–1514.

Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P., Poustka, A., Hunstein, W. & Lichter, P. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580–1588.

Dohner, H., Stilgenbauer, S., James, M.R., Benner, A., Weilgum, T. & Bentz, M. (1997) 11q deletions identify a new subset of B-cell chronic lymphocytic leukaemia characterised by extensive nodal involvement and inferior prognosis. Blood, 89, 2616–2522.

Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of *Medicine*, 343, 1910–1916.

Dreger, P. & Montserrat, E. (2002) Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia, 16, 985–992.

Dreger, P., van Biezen, A., Brand, R., Esteve, J., Gratwohl, A., Kimby, Michallet, M., Milligan, D.W. & Niederwieser, D. (2000a)

Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): the EMBT experience. *Blood*, 96(Suppl. 1), 482a.

Dreger, P., von Neuhoff, N., Sonnen, R., Kuse, R., Seyfarth, B., Glass, B. & Schmitz, N. (2000b) Feasibility and efficacy of autologous stem cell transplantation for poor risk CLL. *Blood*, 96(Suppl. 1), 483a.

Dreger, P., van Biezen, A., Brand, R., Hansz, J., Corradini, P., Finke, J., Lambertenghi-Deliliers, G., Russell, N., Michallet, M. & Niederwieser, D. (2001). Allogenic stem cell transplantation (SCT) for chronic lymphocytic leukaemia using intensity-reduced conditioning.

An EMBT survey. Blood, 98, 743a. Dreger, P., Stilgenbauer, S., Benner, A., Ritgen, M., Schmitz, N. & Dohner, H. (2002) High-dose therapy with autologous stem cell transplantation (ASCT) prolongs survival of patients with chronic lymphocytic leukemia (CLL): a matched-pair analysis. *Blood*, 100(Suppl. 1), 217a.

Dreger, P., Brand, R., Hansz, J., Milligan, D., Corradini, P., Finke, J., Deliliers, G., Martino, R., Russell, N., Van Biezen, A., Michallet, M. & Niederwieser, D. (2003) Treatment related mortality and graft versus leukemia effect after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity reduced conditioning. *Leukemia*, 17, 841–848.

Durig, J., Nascher, M., Schmucker, U., Renzing-Kohler, K., Huttmann, A. & Duhrsen, U. (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. *Leukemia*, 16, 30–35.

Eichhorst, B., Busch, R., Stauch, M., Kneba, M., Ritgen, M., Soling, U., Burkhard, O., Bergmann, M., Wendtner, M., Hiddemann, W., Emmerich, B. & Hallek, M. (2003a) Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil: interim analysis of a phase 111 study of the German CLL study group. *Blood*, 102(Suppl. 1), 109a.

Eichhorst, B., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Soling, U., Siehl, S., Steinbrecher, C., Jager, U., Bergmann, M., Wendtner, M., Hiddemann, W., Emmerich, B. & Hallek, M. (2003b) Fludarabine plus cyclophosphamide induces higher remission rates and longer progression free survival than fludarabine alone in first line therapy of advanced chronic lymphocytic leukemia: results of a phase 111 study of the German CLL study group. *Blood*, 102(Suppl. 1), 72a.

Esteve, J., Montserrat, E., Dreger, P., Meloni, G., Pavletic, S., Catovsky, D., Dearden, D., Scime, C., Sutton, L., Michallet, M., Desablens, B., Kimby, E., Coiffier, B., Brunet, S., Sanz, M.A., Besalduch, J., Cabellero, D., Juliusson, G., Conde, E., Del Potro, E. & Schmitz, N. (2001): Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogenic transplants. *Blood*, 98(Suppl. 1), 482a.

Esteve, J., Vilamor, N., Colomer, D. & Montserrat, E. (2002) Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. *Blood*, 99, 1873–1874.

Ezdinli, E., Stutzman, L., William August, C. & Firat, D. (1969) Corticosteriod therapy for lymphomas and chronic lymphocytic leukemia. *Cancer*, 23, 900–909.

Faderl, S., Thomas, D.A., O'Brian, S., Giles, F., Koller, C.A., Beran, M., Williams, M., Garcia-Manero, G., Kantarjian, H.M. & Keating, M.J. (2001): An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and rituximab in the treatment of CD52- and CD20-positive chronic lymphoid disorders. *Blood*, 98(Suppl. 1), 365a.

Forsyth, P., Milligan, D. & Davies, F.E. (2000): High dose chemoradiotherapy with autologous stem cell rescue for patients with CLL is an effective and safe means of inducing molecular responses: an MRC pilot study. *Blood*, 96(Suppl. 1), 843a.

French Co-operative Group on Chronic Lymphocytic Leukaemia (1990a) Natural history of stage A chronic lymphocytic leukaemia untreated patients. *British Journal of Haematology*, 76, 45–57.

French Co-operative Group on Chronic Lymphocytic Leukaemia (1990b) A randomized clinical trial of chlorambucil versus COP in stage A chronic lymphocytic leukaemia. *French Co-*

operative Group on Chronic Lymphocytic Leukaemia. Blood, 75, 1422–1425.

French Co-operative Group on CLL, Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet, 347, 1432–1438.

Gale, R.P. & Montserrat, E. (1993): Intensive therapy of chronic lymphocytic leukaemia. Bailliere's Clinical Haematology, 6, 879–885.

Galton, D., Wiltshire, E., Szur, J. & Dacie, J. (1961): The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. British Journal of Haematology, 7, 73–98.

Garcia-Manero, G., O'Brien, S., Cortes, J., Faderl, S., Giles, F., Albitar, M., Lerner, S., Kantarjian, H. & Keating, M. (2001) Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL). Blood, 98(Suppl. 1), 633a.

Ghazal, H. (2002) Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood, 99, 1092–1094.

Ghia, P., Guida, G., Stella, S., Gottardi, D., Guena, M., Strola, G., Scielzo, C. & Caligaris-Cappio, F. (2003): The pattern of CD38 expression defines a distinct subset of chronic

lymphocytic leukemia (CLL) patients at risk of disease progression. *Blood*, 101, 1262–1269.

iles, F.J., O'Brien, S.M. & Keating, M.J. (1998) Chronic lymphocytic leukemia in (Richter's) transformation. *Seminars in Oncology*, 25, 117–125.

Giles, F.J., O'Brien, S.M., Santini, V., Gandhi, V., Plunkett, W., Seymour, J.F., Robertson, L.E., Kantarjian, H.M. & Keating, M.J. (1999) Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. *Leukemia and Lymphoma*, 36, 57–65.

Girinsky, T., Guillot-Vals, D., Koscielny, S., Cosset, J.M., Ganem, G., Carde, P., Monhonval, M., Pereira, R., Bosq, J., Ribrag, V., Vantelon, J.M. & Munck, J.N. (2001) A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. *International Journal of Radiation Oncology, Biology, Physics*, 51, 148–155.

Grever, M.R., Kopecky, K.J., Coltman, C.A., Files, J.C., Greenberg, B.R., Hutton, J.J., Talley, R., Von Hoff, D.D. & Balcerzak, S.P. (1988) Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukaemia. *Nouvelle Revue Francaise d'Hematologie*, 30, 457–459.

Gribabis, D.A., Panayiotidis, P., Boussiotis, V.A., Hannoun, C. & Pangalis, G.A. (1994) Influenza virus vaccine in B-cell

chronic lymphocytic leukaemia patients. *Acta Haematologica*, 91, 115–118.

Gribben, J.C., Neuberg, D., Soiffer, R.J., Fischer, D.C., Schlossman, R., Alyea, E.P., Kuhlman, C., Ritz, J. & Nadler, L.M. (1998) Autologous versus allogenic bone marrow transplantation for patients with poor prognosis *CLL*. *Blood*, 92(Suppl.), 322a.

Griffiths, H., Brennan, V., Lea, J., Bunch, C., Lee, M. & Chapel, H. (1989) Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. *Blood*, 73, 366–368.

Gupta, N.K., Patel, D., Kavuru, S., Janson, D., Hoffman, M., Ramadoss, U., Ahmed, S. & Rai, K. (2001) Rituximab, cyclophosphamide and decadron (RCD) is effective in previously treated advanced chronic lymphocytic leukaemia (CLL). *Journal of Clinical Oncology*, 20, page 284a (abstract no. 1133).

Gupta, N.K., Kavuru, S., Patel, D., Janson, D., Driscoll, N. & Ahmed, S. (2002) Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. *Leukemia*, 10, 2092–2095.

Hainsworth, J., Litchy, S., Barton, J., Houston, G., Hermann, F., Bradof, J. & Greco, F. (2003) Single agent rituximab as first line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. *Journal of Clinical Oncology*, 21, 1746–1751.

Hallek, M., Langenmayer, I., Nerl, C., Knauf, W., Dietzfelbinger, H., Adorf, D., Ostwald, M., Busch, R., Kuhn-Hallek, I., Thiel, E. & Emmerich, B. (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. *Blood*, 93, 1732– 1737.

Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H.P., Sezer, O., Herold, M., Knauf, W., Wendtner, C.M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G., Emmerich, B. & the German Chronic Lymphocytic Leukaemia Study Group (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. *British Journal of Haematology*, 114, 342–348.

Hamblin, T. (2001) Autoimmune Disease and Its Management in Chronic Lymphocytic Leukemia. In: *Chronic Lymphoid Leukemias* (ed. by B.D. Cheson), pp. 435–458.

Marcel Dekker, New York. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood*, 94, 1848– 1854.

Hamblin, T.J., Orchard, J.A., Ibbotson, R.E., Davis, Z., Thomas, P.W., Stevenson, F.K. & Oscier, D.G. (2002) CD38 expression and immunoglobulin variable region mutations are

independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. *Blood*, 99, 1023–1029.

Han, T., Ezdinli, E.Z., Shimaoka, K. & Desai, D.V. (1973)
Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. *Cancer*, 31, 502–508.

Hegde, U.P., Wyndham, H.W., White, T. & Cheson, B.D. (2002)
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. *Blood*, 100, 2260–2262.

Hensel, M., Kornacker, M., Yammeni, S., Egerer, G. & Ho, A. (2003)
Disease activity and pretreatment rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, 122, 600–606.

Horowitz, M.M., Montserrat, E., Sobocinski, K., Giral, S., Khouri, I.F. & Schmitz, N. (2000) Haemopoietic stem cell transplantation for chronic lymphocytic leukaemia. *Blood*, 96(Suppl. 1), 522a.

Houlston, R., Catovsky, D. & Yuille, M. (2002) Genetic susceptibility to chronic lymphocytic leukemia. *Leukemia*, 16, 1008–1014.

Juliusson, G. & Liliemark, J. (1994) Retreatment of chronic lymphocytic leukaemia with 2-chlorodeoxyadenosine (CdA)

at relapse following CdA-induced remission: no acquired resistance. *Leukemia and Lymphoma*, 13, 75–80. *n*

Ibrahim, S., Keating, M., Do, K.A., O'Brien, S., Huh, Y.O., Jilani, I., Lerner, S., Kantarjian, H.M. & Albitar, M. (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. *Blood*, 98, 181–186.

Jaksic, B. & Brugiatelli, M. (1988) High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL–IGCI CLL-01 trial. *Nouvelle Review Francais d'Hematologie*, 30, 437–442.

Jaksic, B. & Vitale, B. (1981) Total tumour mass score (TTM): a new parameter in chronic lymphocyte leukaemia. *British Journal of Haematology*, 49, 405–413.

Jaksic, B., Brugiatelli, M., Krc, I., Losonczi, H., Holowiecki, J., Planinc- Peraica, A., Kusec, R., Morabito, F., Iacopino, P. & Lutz, D. (1997) High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. *International Society for Chemo-Immunotherapy, Vienna. Cancer*, 79, 2107–2114.

Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine

versus cyclophosphamide, doxorubicin, and prednisilone (CAP) for the treatment of advanced-stage chronic lymphocytic leukaemia. The French Co-operative Group on CLL. *Lancet*, 347, 1432–1438.

Juliusson, G. & Liliemark, J. (1993) High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukaemia: response predicted by rapid decrease of blood lymphocyte count. *Journal of Clinical Oncology*, 11, 679–689.

Juliusson, G. & Liliemark, J. (1994) Retreatment of chronic lymphocytic leukaemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. *Leukemia and Lymphoma*, 13, 75–80.

Juliusson, G. & Liliemark, J. (1996) Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukaemia. *Annals of Oncology*, 7, 373–379.

Juliusson, G., Oscier, D.G., Fitchett, M., Ross, F.M., Stockdill, G., Mackie, M.J., Parker, A.C., Castoldi, G.L., Cuneo, A., Knuutila, S., Elonen, E. & Gahrton, G. (1990) Prognostic subgroups in B-cell chronic lymphocytic leukaemia defined by specific chromosomal abnormalities. *New England Journal of Medicine*, 323, 720–724.

Juliusson, G., Elmhorn-Rosenborg, A. & Liliemark, J. (1992) Response to chlorodeoxyadenosine in patients with B-cell chronic

lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine, 327, 1056–1061.

Juliusson, G., Christiansen, I., Hansen, M.M., Johnson, S., Kimby, E., Elmhorn-Rosenborg, A. & Liliemark, J. (1996) Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. Journal of Clinical Oncology, 14, 2160–2166.

Jurlander, J., Geisler, C.H. & Hansen, M.M. (1994) Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. European Journal of Hematology, 53, 114–118.

Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J. & McCredie, K.B. (1988) Fludarabine therapy in chronic lymphocytic leukaemia (CLL). Nouvelle Revue Francaise d'Hematologie, 30, 461–466.

Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J. & McCredie, K.B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukaemia. Blood, 74, 19–25.

Keating, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. & Kantarjian, H. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92, 1165–1171.

Keating, M.J., Smith, T.L., Lerner, S., O'Brien, S., Robertson, L.E., Kantarjian, H. & Freireich, E.J. (2000) Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukaemia. *Leukemia and Lymphoma*, 37, 71–85.

Keating, M.J., Manshouri, T., O'Brien, S., Wierda, W., Kantarjian, H., Washington, L., Lerner, S. & Abitar, M. (2002a) A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukaemia (CLL). *Blood*, 100 (Part 1), 205a.

Keating, M.J., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S. & Kantarjian, H. (2002b) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukaemia. *Leukemia and Lymphoma*, 43, 1755–1762.

Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002c) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. *Blood*, 99, 3554–3561.

Kennedy, B., Rawstron, A., Haynes, A., Fegan, C., Leach, M., Tighe, J., Rassam, S., Hale, G., Morgan, G. & Hillmen, P. (2001) Eradication of detectable minimal residual disease with Campath-1H therapy results in prolonged survival in patients with refractory B-CLL. *Blood*, 98(Suppl. 1), 365a.

Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G. & Hillmen, P. (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. *Blood*, 99, 2245–2247.

Knauf, W.U., Ehlers, B., Mohr, B., Thiel, E., Langenmayer, I., Hallek, M., Emmerich, B., Adorf, D., Nerl, C. & Zwingers, T. (1997) Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. *Blood*, 89, 4241–4242.

Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Dohner, H. & Stilgenbauer, S. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. *Blood*, 100, 1410–1416.

Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. *Blood*, 98, 2319–2325.

Lin, K., Sherrington, P.D., Dennis, M., Matrai, Z., Cawley, J.C. & Pettitt, A.R. (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. *Blood*, 100, 1404–1409.

Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). *Blood*, 100, 768–773.

Mauro, F.R., Foa, R., Giannarelli, D., Cordone, I., Crescenzi, S., Pescarmona, E., Sala, R., Cerretti, R. & Mandelli, F. (1999) Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single *institution study of*

Mauro, F.R., Foa, R., Cerretti, R., Giannarelli, D., Coluzzi, S., Mandelli, F. & Girelli, G. (2000) Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. *Blood*, 95, 2786–2792.

Michallet, M., Carreras, E., Cornelissen, J.J., Dreger, P., Einsele, H., Gratwohl, A., Kimby, E., Niederwieser, D. & Apperley, J. (1999) Allografts and autografts in CLL (abstract). *Bone Marrow Transplantation*, 23, S53.

Michallet, M., Thiebaud, A., Dreger, P., Remes, K., Milpied, N., Santini, G., Hamon, M., Bjorkstrand, B., Kimby, E., Belhabri, A., Tanguy, M. & Apperley, J. (2000) Peripheral blood stem cell mobilisation and transplantation after

fludarabine therapy in chronic lymphocytic leukaemia: a report of the EBMT CLL Subcommittee on behalf of the EBMT Chronic Leukaemia Working Party. *British Journal of Haematology*, 108, 595–601.

Molica, S. (1994) Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. *Leukemia and Lymphoma*, 13, 203–214.

Monteserrat, N., Vinolas, N., Reverter, J.C. & Rozman, C. (1988) Natural history of chronic lymphocytic leukaemia: on the progression and prognosis of early stages. *Nouvelle Review Francais d'Hematologie*, 30, 359–361.

Montillo, M., Tedeschi, A., Cafro, A.M., Rossi, V., D'Avanzo, G.,

Pungolino, E., Cairoli, R., Oreste, P., Veronese, S., Brando, B. & Morra, E. (2002) Sequential subcutaneous administration of CAMPATH-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP). *Blood*, 100(Suppl. 1), 805a.

Montillo, M., Tedeschi, A., O'Brien, S., DiRaimondo, F., Lerner, S., Ferrajoli, A., Morra, E. & Keating, M. (2003) Phase 11 study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. *Cancer*, 79, 114–120.

Montserrat, E. & Rozman, C. (1993) Chronic lymphocytic leukaemia: prognostic factors and natural history. *Bailliere's Clinical Haematology*, 6, 849–866.

Montserrat, E., Alcala, A., Parody, R., Domingo, A., Garcia-Conde, J., Bueno, J., Ferran, C., Sanz, M.A., Giral, M. & Rubio, D. (1985): Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial, comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. *Cancer*, 56, 2369–2375.

Montserrat, E., Gomis, F., Vallespi, T., Rios, A., Romero, A., Soler, J., Alcala, A., Morey, M., Ferran, C., Diaz-Mediavilla, J., Flores, A., Woessner, S., Batlle, J., Gonzales-Aza, C., Rovira, M., Reverter, J. & Rozman, C. (1991) Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. *Blood*, 78, 1545–1551.

Montserrat, E., Lopez-Lorenzo, J.L., Manso, F., Martin, A., Prieto, E., Arias-Sampedro, J., Fernandez, M.N., Oyarzabal, F.J., Odriozola, J., Alcala, A., Garcia-Conde, J., Guardia, R. & Bosch, F. (1996) Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. *Leukaemia and Lymphoma*, 21, 467–472.

Moreau, E.J., Matutes, E., A'Hern, R.P., Morilla, A.M., Morilla, R.M., Owusu-Ankomah, K.A., Seon, B.K. & Catovsky, D. (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). *American Journal of Clinical Pathology*, 108, 378–382.

Morrison, V.A. (2001) Infections in Patients with Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum and Therapeutic

Approaches. In: Chronic Lymphoid Leukemias (ed. by B.D. Cheson), pp. 505–523. Marcel Dekker, New York.

Morrison, V.A., Rai, K.R., Peterson, B.L., Kolitz, J.E., Elias, L., Appelbaum, F.R., Hines, J.D., Shepherd, L., Larson, R.A. & Schiffer, C.A. (2002) Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. *Journal of Clinical Oncology*, 20, 3878– 3884.

Myint, H., Copplesstone, J.A., Orchard, J., Craig, V., Curtis, D., Prentice, A.G., Hamon, M.D., Oscier, D.G. & Hamblin, T.J. (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, 91, 341–344.

Nabhan, C., Tallman, M.S. & Riley, M.B. (2001) Phase 1 study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukaemia. *Blood*, 98(Suppl. 1), 365a.

National Institute for Clinical Excellence (2001) Guidance on the use of fludarabine for B-cell lymphocytic leukaemia. Technology Appraisal Guidance 29. National Institute for Clinical Excellence, London.

Neal, Jr, T.F., Tefferi, A., Witzig, T.E., Su, J., Phylipy, R.L. & Nagorney, D.M. (1992) Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients. *American Journal of Medicine*, 93, 435–440.

O'Brien, S., Kantarjian, H., Beran, M., Smith, T., Koller, C., Estey, E., Robertson, L.E., Lerner, S. & Keating, M. (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. *Blood*, 82, 1695–1700.

O'Brien, S., Kantarjian, H., Beran, M., Koller, C., Talpaz, M., Lerner, S. & Keating, M.J. (1997) Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. *Leukemia*, 11, 1631–1635.

O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. *Journal of Clinical Oncology*, 19, 1414–1420.

O'Brien, S.M., Kantarjian, H.M., Thomas, D.A., Cortes, J., Giles, F.J., Wierda, W.G., Koller, C.A., Ferrajoli, A., Browning, M., Lerner, S., Abitar, M. & Keating, M.J. (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. *Cancer*, 98, 2657–2663.

Orchard, J.A., Ibbotson, R.E., Davis, Z.A., Gardiner, A.C., Hamblin, T.J. & Oscier, D.G. (2004) Zap-70 evaluation by flow cytometry is a significant prognostic marker in B-CLL. *Lancet*, 363, 105–111.

Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. & Hamblin, T.J. (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. *Blood*, 100, 1177–1184.

Osterborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. & Mellstedt, H. (1996) humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. *British Journal of Haematology*, 93, 151–153.

Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, 15, 1567–1574.

Pegourie, B., Sotto, J.J., Hollard, D., Michallet, M. & Sotto, M.F. (1987) Splenectomy during chronic lymphocytic leukemia. *Cancer*, 59, 1626–1630.

Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone,

A.H., Linch, D.C., San Miguel, J.F. & Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. *Blood*, 100, 3121–3127.

Perkins, J.G., Flynn, J.M., Howard, R.S. & Byrd, J.C. (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. *Cancer*, 94, 2033–2039.

Pfützner, T., Reiser, M., Barth, S., Borchmann, P., Schulz, H., Schinkothe, T., Oberhauser, F., Wessels, J., Tur, M., Diehl, V. & Engert, A. (2002) Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. *Annals of Hematology*, 81, 258–266.

Piro, L.D., Carrera, C.J., Beutler, E. & Carson, D.A. (1988) 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. *Blood*, 72, 1069–1073.

Rabinowe, S.N., Soiffer, R.J., Gribben, J.G., Daley, H., Freedman, A.S., Daley, J., Pesek, K., Neuberg, D., Pinkus, G. & Leavitt, P.R. (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. *Blood*, 82, 1366–1376.

- Rai, K.I., Sawitsky, A., Cronkite, E.P., Chanana, A., Levy, R. & Pasternak, B. (1975)** Clinical staging of chronic lymphocytic leukaemia. *Blood*, 46, 219–234.
- Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000)** Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *New England Journal of Medicine*, 343, 1750–1757.
- Rai, K., Coutre, S., Rizzieri, D., Gribben, J., Flinn, I., Rabinowe, S. & Keating, M. (2001)** Efficacy and safety of alemtuzumab (Campath- 1H) in refractory B-CLL patients treated on a compassionate basis. *Blood*, 98(Suppl. 1), 365a.
- Raphael, B., Andersen, J.W., Silber, R., Oken, M., Moore, D. & Bennett, J. (1991)** Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine and prednisone as an initial treatment for chronic lymphocytic leukaemia: a long term follow up of an Eastern Co-operative Oncology Group randomised clinical trial. *Journal of Clinical Oncology*, 9, 770–776.
- Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001)** Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. *Blood*, 98, 29–35.

Rawstron, A.C., Yuille, M.R., Fuller, J., Cullen, M., Kennedy, B., Richards, S.J., Jack, A.S., Matutes, E., Catovsky, D., Hillmen, P. & Houlston, R.S. (2002) Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. *Blood*, 100, 2289–2290.

Richter, M.N. (1928) Generalised reticular cell sarcoma of lymph nodes associated with lymphocytic leukemia. *American Journal of Pathology*, 4, 285–292.

Ritgen, M., Dreger, P., Humpe, A., Stilgenbauer, S., Döhner, H. & Kneba, M. (2002). Quantitative PCR demonstrates effective graft versus host leukemia activity after allogeneic stem cell transplantation using reduced intensity conditioning in patients with chronic lymphocytic leukemia. *Blood*, 100(Suppl. 1), 854a.

Ritgen, M., Lange, A., Stilgenbauer, S., Dohner, H., Bretscher, C., Bosse, H., Stuhr, A., Kneba, M. & Dreger, P. (2003) Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. *Blood*, 101, 2049–2053.

Robak, T. & Kasznicki, M. (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. *Leukemia*, 16, 1015–1027.

Robak, T., Blonski, J.Z., Kasznicki, M., Blasinska-Morawiec, M., Krykowski, E., Dmoszynska, A., Mrugala-Spiewak, H., Skotnicki, A.B., Nowak, W., Konopka, L., Ceglarek, B., Maj, S., Dwilewicz-Trojaczek, J., Hellmann, A., Urasinski, I., Zdziarska, B., Kotlarek-Haus, S., Potoczek, S. & Grieb, P. (2000a) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. *Blood*, 96, 2723–2729.

Robak, T., Blonski, J.Z., Kasznicki, M., Konopka, L., Ceglarek, B., Dmoszynska, A., Soroka-Wojtaszko, M., Skotnicki, A.B., Nowak, W., Dwilewicz-Trojaczek, J., Tomaszewska, A., Hellman, A., Lewandowski, K., Kuliczkowski, K., Potoczek, S., Zdziarska, B., Hansz, J., Kroll, R., Komarnicki, M., Holowiecki, J. & Grieb, P. (2000b) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia – updated results of the multicentre study of 378 patients. *British Journal of Haematology*, 108, 357–368.

Robertson, L.E., Pugh, W., O'Brien, S., Kantarjian, H., Hirsch-Ginsberg, C., Cork, A., McLaughlin, P., Cabanillas, F. & Keating, M.J. (1993) Richter's syndrome: a report on 39 patients. *Journal of Clinical Oncology*, 11, 1985–1989.

Ru, X. & Liebman, H. (2003) Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders

with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). *British Journal of Haematology*, 123, 278–281.

Rummel, M.J., Kafer, G., Pfreundschuh, M., Jager, E., Reinhardt, U., Mitrou, P.S., Hoelzer, D. & Bergmann, L. (1999) Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German Multicentre phase II study. *Annals of Oncology*, 10, 183–188.

Saven, A., Carrera, C.J., Carson, D.A., Beutler, E. & Piro, L.D. (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukaemia. *Leukemia and Lymphoma*, 5(Suppl.), 133–138.

Saven, A., Lemon, R.H., Kosty, M., Beutler, E. & Piro, L.D. (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukaemia. *Journal of Clinical Oncology*, 14, 2160–2166.

Sawitsky, A., Rai, K.R., Glidewell, O. & Silver, R.T. (1979) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. *Blood*, 50, 1049–1059.

Schulz, H., Klein, S.K., Rehwald, U., Reiser, M., Hinke, A., Knauf, W.U., Aulitzky, W.E., Hensel, M., Herold, M., Huhn, D., Hallek, M., Diehl, V. & Engert, A. (2002) Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. *Blood*, 100, 3115–3120.

- Schwarzmeier, J.D., Shehata, M., Hilgarth, M., Marschitz, I., Louda, N., Hubmann, R. & Greil, R. (2002)** The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. *Leukemia and Lymphoma*, 43, 549–554.
- Seymour, J.F., Cusack, J.D., Lerner, S.A., Pollock, R.E. & Keating, M.J. (1997)** Case/control study of the role of splenectomy in chronic lymphocytic leukemia. *Journal of Clinical Oncology*, 15, 52–60.
- Sgambati, M.T., Linet, M.S. & Devesa, S.S. (2001)** Chronic Lymphocytic Leukemia: Epidemiological, Familial, and Genetic Aspects. In: *Chronic Lymphoid Leukemias* (ed. by B.D. Cheson), pp. 33–62.
- Marcel Dekker, New York. Sinisalo, M., Aittoniemi, J., Oivanen, P., Kayhty, H., Olander, R.M. & Vilpo, J. (2001)** Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, 114, 107–110.
- Sinisalo, M., Aittoniemi, J., Kayhty, H. & Vilpo, J. (2003)** Vaccination strategies against infections in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, 44, 649–652.
- Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. & Cheson, B.D. (1997)** Treatment of refractory chronic lymphocytic leukaemia with fludarabine phosphate via the Group C Protocol mechanism of the National Cancer Institute: five-year follow-up report. *Journal of Clinical Oncology*, 15, 458–465.

Stilgenbauer, S. & Dohner, H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. *New England Journal of Medicine*, 347, 452–453.

Stilgenbauer, S., Neuhoﬀ, N., Bullinger, L., Krober, A., Lichter, P., Dreger, P. & Dohner, H. (2000) Deletion 11q23 identifies B-CLL patients at high risk for molecular disease persistence after high dose therapy and autografting. *Blood*, 96(Suppl. 1), 715a.

Thornton, P.D., Matutes, E., Bosanquet, A.G., Lakhani, A.K., Grech, H., Ropner, J.E., Joshi, R., Mackie, P.H., Douglas, I.D., Bowcock, S.J. & Catovsky, D. (2003) High dose methyl prednisolone can induce remissions in CLL patients with p53 abnormalities. *Annals of Hematology*, Oct 10, (E-pub ahead of print).

Tobin, G., Thurnberg, U., Johnson, A., Thorn, I., Soderberg, O., Hultdin, M., Botling, J., Enblad, G., Sallstrom, J., Sundstrom, C., Roos, G. & Rosenquist, R. (2002) Somaticallv mutated Ig VH3–21 genes characterize a new subset of chronic lymphocytic leukemia. *Blood*, 99, 2262–2264.

Tournilhac, O., Cazin, B., Lepretre, S., Devine, M., Maloum, K., Delmer, A., Grosbois, B., Feugier, P., Maloisel, F., Villard, F., Villemagne, B., Bastit, D., Belhadj, K., Azar, N., Michallet, M., Manhes, G. & Travade, P. (2004). Impact of frontline fludarabine and cyclophosphamide treatment on

peripheral blood stem cell mobilization in B cell chronic lymphocytic leukemia. *Blood*, 103, 363–365.

Van Besien, K., Keralavarma, B., Devine, S. & Stock, W. (2001) Allogeneic and autologous transplantation for chronic lymphocytic leukemia. *Leukemia*, 15, 1317–1325.

Van Mook, W.N., Fickers, M.M. & Verschueren, T.A. (2001) Clinical and immunological evaluation of primary splenic irradiation in chronic lymphocytic leukemia: a study of 24 cases. *Annals of Hematology*, 80, 216–223.

Weeks, J.C., Tierney, M.R. & Weinstein, M.C. (1991) Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. *New England Journal of Medicine*, 325, 81–86.

Weiss, R.B., Freiman, J., Kweder, S.L., Diehl, L.F. & Byrd, J.C. (1998) Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. *Journal of Clinical Oncology*, 16, 1885–1889.

Wierda, W., O'Brien, S., Fader, S., Ferrajoli, A., Lerner, S., Wang, X., Thomas, D., Garcia-Manero, G., Cortes, J., Kantarjian, H. & Keating, M. (2003) Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. *Blood*, 102(Suppl. 1), 110a.

Yuille, M.R., Houlston, R.S. & Catovsky, D. (1998) Anticipation in familial chronic lymphocytic leukaemia. *Leukemia*, 12, 1696–1698.

Wiestner, A., Rosenwald, A., Barry, T.S., Wright, G., Davis, E., Henrickson, S., Zhao, H., Ibbotson, R., Orchard, J., Davis, Z., Stetler- Stevenson, M., Raffeld, M., Arthur, D.C., Marti, G., Wilson, W.H., Hamblin, T., Oscier, D. & Staudt, L. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. *Blood*, 101, 4944–495

Yuille, M.R., Houlston, R.S. & Catovsky, D. (1998) Anticipation in familial chronic lymphocytic leukaemia. *Leukemia*, 12, 1696–1698.

- **Zittoun, R., de Witte, T., et al, (1999)** A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. *Hematology and Cell Therapy*, 41,127–136. Taylor PC. Antibody therapy for. chronic lymphocytic leukemia *Curr Opin Pharmacol*. 2003;3(3):323-328.